Living with Wilson A patient-led project

← Back to all answers

My genetic test shows one ATP7B mutation — am I a carrier or could I develop Wilson disease?

One ATP7B mutation almost certainly makes you a carrier who will not develop Wilson disease, but rare exceptions exist — and one situation does require a closer look at your genetics report.

If your genetic test came back showing one ATP7B mutation, the most likely explanation is that you are a carrier: you inherited one abnormal copy of the gene from one parent and one normal copy from the other. For Wilson disease to develop, a person generally needs two non-functional copies of ATP7B — one from each parent.1 Carriers with a single clearly pathogenic mutation on one copy do not accumulate copper to disease levels and are not expected to develop symptoms.

That is the reassuring news. But there are a few nuances worth understanding, because “one mutation” is not always as simple as it sounds.

Wilson disease is autosomal recessive — what that means for you

Wilson disease follows what geneticists call an autosomal recessive inheritance pattern. Think of it this way: each parent passes one copy of the ATP7B gene to each child. If you received a working copy from one parent and a faulty copy from the other, your single working copy is enough to keep your copper metabolism functioning normally.12

What carriers cannot do is pass Wilson disease itself to their children — they can only pass the mutation. Your children would only be at risk if your partner also carries an ATP7B mutation, and the child inherits a faulty copy from each of you. That is why family planning discussions for carriers often involve family screening.

The “one mutation” report: what it actually means

Here is where it gets a little more technical, and why the exact wording of your report matters. There are two different reasons you might see “one ATP7B mutation” on a genetic report:

Scenario A — True heterozygous carrier. One pathogenic mutation is identified on one copy of chromosome 13. The other copy is sequenced and appears normal. This is the classic carrier situation, and the medical consensus is that these individuals do not develop Wilson disease.3

Scenario B — Compound heterozygote with a second mutation missed. Occasionally, a second mutation exists but is harder to detect — for example, a large deletion or a mutation in a region the standard panel does not cover. In published cohorts, compound heterozygosity (two different mutations, one on each chromosome) is actually quite common in Wilson disease patients — some studies find it in 30–40% of affected individuals.4 If your testing only looked at certain common mutations, it is possible (though not the first assumption) that a second mutation was not detected.

The way to tell these scenarios apart is to ask your genetic counselor whether both copies of the ATP7B gene were fully sequenced, or whether only a targeted panel of known mutations was run. If you are uncertain, a conversation with a genetics team or a specialist with Wilson disease experience is worth having.

Can carriers ever develop any symptoms?

This question comes up often in online communities, and the answer is: rarely and mildly, if ever. A small number of studies have looked at carriers more carefully and found subtle changes in liver enzymes or copper metabolism parameters in some of them, but these generally do not progress to clinical Wilson disease.35

There is no established evidence that being a carrier causes symptomatic liver disease, neurological symptoms, or any other clinical presentation that would require treatment. If you are having health problems, it is worth investigating those problems on their own terms — but attributing them to carrier status alone is not supported by current evidence.

What about your children — and your siblings?

Carrying one ATP7B mutation has implications for your family:

Your children. Each child has a 50% chance of inheriting your mutation. If your partner has no ATP7B mutations (likely if they have no family history and no symptoms), your children’s risk of Wilson disease is very low — they could be carriers at most. If your partner’s carrier status is unknown, family screening can clarify the picture.6

Your siblings. If you inherited a mutation from one parent, there is a 50% chance each sibling inherited the same mutation from that parent. More importantly: if the same parent also has a second mutation on the other copy (meaning that parent has Wilson disease or is a compound heterozygote), a sibling could have inherited two mutations. This is the scenario that makes sibling genetic testing worthwhile after a new diagnosis in any family.6

Your parents. One of your parents is also a carrier of the mutation you carry. In rare cases, that parent may have two mutations and have undiagnosed or mildly expressed Wilson disease — though if they are healthy and middle-aged, this is unlikely.

What happens to your monitoring

If you are a confirmed carrier with a single clearly pathogenic mutation on one chromosome and a normal second chromosome, current guidelines do not recommend copper monitoring or treatment.12 You do not need to follow a special low-copper diet. You can drink alcohol in the same moderation recommended for the general population — though see alcohol and Wilson disease for context about liver health generally.

If your report is ambiguous — for example, it says “variant of uncertain significance” rather than a clearly pathogenic mutation, or if only a partial panel was done — that is a reason to seek genetic counseling before assuming you are simply a carrier.

Questions to ask your genetic counselor

Bring these to your next appointment:

  • Was the full coding sequence of both ATP7B gene copies tested, or was a panel of known mutations used?
  • Is my identified variant classified as pathogenic, likely pathogenic, or a variant of uncertain significance?
  • What is the probability, given the testing method used, that a second mutation could have been missed?
  • Do you recommend any liver function testing as a baseline?

This post is patient education, not medical or genetic advice. Genetic reports can be complex, and a genetic counselor is the right person to interpret your specific result in the context of your family history. If you have concerns about your result, please speak with your physician or a certified genetic counselor.

References


  1. Czlonkowska, Anna, Tomasz Litwin, Petr Dusek, et al. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. 

  2. Schilsky, Michael L., Kris V. Kowdley, Brendan M. McGuire, et al. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance from the American Association for the Study of Liver Diseases.” Hepatology 77, no. 4 (2023): 1428–1455. https://doi.org/10.1002/hep.32801. 

  3. European Association for Study of Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. 

  4. Vrabelova, Sarka, Ondrej Letocha, Miroslav Borsky, et al. “Mutation Analysis of the ATP7B Gene and Genotype/Phenotype Correlation in 227 Patients with Wilson Disease.” Molecular Genetics and Metabolism 86, no. 1–2 (2005): 277–285. https://doi.org/10.1016/j.ymgme.2005.05.004. 

  5. Alkhouri, Naim, and Tarun Mullick. “Wilson Disease: Review of Diagnosis and Management.” Hepatology Communications 7, no. 8 (2023): e0150. https://doi.org/10.1097/HC9.0000000000000150. 

  6. Prasad, Vivek N. “Family Screening by Genetic Testing Helps to Prevent Disease.” Journal of Clinical and Experimental Hepatology 14, no. 3 (2024): 102341. https://doi.org/10.1016/j.jceh.2024.102341. 

  7. Zimbrean, Paula C., and Michael L. Schilsky. “Psychiatric Aspects of Wilson Disease: A Review.” General Hospital Psychiatry 36, no. 1 (2014): 53–62. https://doi.org/10.1016/j.genhosppsych.2013.08.007. 

  8. Weinstein, David A., and Shetal Shah. “Wilson Disease and Pregnancy.” Clinical Liver Disease 23, no. 3 (2024): e0110. https://doi.org/10.1097/cld.0000000000000110. 

This is patient education, not medical advice. Always consult your own clinical team about decisions for your care.